Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

References

• HongMCHsuDIBounthavongMCeftolozane/tazobactam: a novel antipseudomonal cephalosporin and beta-lactamase-inhibitor combinationInfect Drug Resist2013621522324348053
   PubMedGoogle Scholar
• MitraSSaeedUHavlichekDHSteinGEProfile of oritavancin and its potential in the treatment of acute bacterial skin structure infectionsInfect Drug Resist2015818919726185459
   PubMed Web of Science ®Google Scholar
• CDC [webpage on the Internet]Antibiotic Resistance Threats in the United States2013 Available from: http://www.cdc.gov/drugresistance/threat-report-2013/Accessed December 30, 2015
   Google Scholar
• RedgraveLSSuttonSBWebberMAPiddockLJFluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary successTrends Microbiol201422843844524842194
   PubMed Web of Science ®Google Scholar
• CovingtonPDavenportJMAndraeDRandomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infectionAntimicrob Agents Chemother201155125790579721947389
   PubMed Web of Science ®Google Scholar
• BiedenbachDJFarrellDJFlammRKLivermanLCMcIntyreGJonesRNActivity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumoniaInt J Antimicrob Agents201239432132522306239
   PubMed Web of Science ®Google Scholar
• BlumbergHMRimlandDCarrollDJTerryPWachsmuthIKRapid development of ciprofloxacin resistance in methicillin-susceptible and-resistant Staphylococcus aureusJ Infect Dis19911636127912852037793
   PubMed Web of Science ®Google Scholar
• JonesRNMendesRESaderHSCeftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance studyJ Antimicrob Chemother201065Suppl 4iv17iv3121115451
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of AmericaClin Infect Dis201459214715924947530
   PubMed Web of Science ®Google Scholar
• MandellLAWunderinkRGAnzuetoAInfectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adultsClin Infect Dis200744Suppl 2S27S7217278083
   PubMed Web of Science ®Google Scholar
• TomicVDowzickyMJRegional and global antimicrobial susceptibility among isolates of Streptococcus pneumoniae and Haemophilus influenzae collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004–2008)Ann Clin Microbiol Antimicrob2014135225376749
   PubMed Web of Science ®Google Scholar
• JonesRNSaderHSMendesREFlammRKUpdate on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011)Diagn Microbiol Infect Dis201375110710923009730
   PubMed Web of Science ®Google Scholar
• LeeBBoucherHWTargeting antimicrobial-resistant bacterial respiratory tract pathogens: it is time to ‘get smart’Curr Opin Pulm Med201521329330325784248
   PubMed Web of Science ®Google Scholar
• MorrowBJHeWAmslerKMIn vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinoloneAntimicrob Agents Chemother20105451955196420176911
   PubMed Web of Science ®Google Scholar
• MorrowBJAbbanatDBaumEZAntistaphylococcal activities of the new fluoroquinolone JNJ-Q2Antimicrob Agents Chemother201155125512552121911562
   PubMed Web of Science ®Google Scholar
• Van BambekeFRenaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolonesAnn Med201446751252925058176
   PubMed Web of Science ®Google Scholar
• CovingtonPSDavenportJMAndraeDAA Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumoniaJ Antimicrob Chemother201368112691269323749951
   PubMed Web of Science ®Google Scholar
• OwensRCJrAmbrosePGAntimicrobial safety: focus on fluoroquinolonesClin Infect Dis200541Suppl 2S144S15715942881
   PubMed Web of Science ®Google Scholar
• AndrioleVTThe quinolones: past, present, and futureClin Infect Dis200541Suppl 2S113S11915942877
   PubMed Web of Science ®Google Scholar
• DomagalaJMStructure-activity and structure-side-effect relationships for the quinolone antibacterialsJ Antimicrob Chemother19943346857068056688
   PubMed Web of Science ®Google Scholar
• KarpiukITyskiSLooking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trialsPrzegl Epidemiol201367345546055746124340560
   PubMedGoogle Scholar
• ZhaoXXuCDomagalaJDrlicaKDNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistanceProc Natl Acad Sci U S A1997942513991139969391140
   PubMed Web of Science ®Google Scholar
• FarrellDJLivermanLCBiedenbachDJFlammRKJonesRNSurveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic Streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance ProgramDiagn Microbiol Infect Dis201171441542021982563
   PubMed Web of Science ®Google Scholar
• FarrellDJLivermanLCBiedenbachDJJonesRNJNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strainsAntimicrob Agents Chemother20115573631363421555765
   PubMed Web of Science ®Google Scholar
• FernandezJHilliardJJMorrowBJEfficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infectionsAntimicrob Agents Chemother201155125522552821911568
   PubMed Web of Science ®Google Scholar
• KaatzGWMoudgalVVSeoSMIdentification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureusJ Antimicrob Chemother200250683383812461001
   PubMed Web of Science ®Google Scholar
• DrlicaKMalikMFluoroquinolones: action and resistanceCurr Top Med Chem20033324928212570763
   PubMed Web of Science ®Google Scholar
• FirsovAAVostrovSNLubenkoIYDrlicaKPortnoyYAZinnerSHIn vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureusAntimicrob Agents Chemother20034751604161312709329
   PubMed Web of Science ®Google Scholar
• DavenportJMCovingtonPGotfriedMSummary of pharmacokinetics and tissue distribution of a broad-spectrum fluoroquinolone, JNJ-Q2Clin Pharmacol Drug Dev20121412113027121454
   PubMed Web of Science ®Google Scholar
• SullivanJTWoodruffMLettieriJPharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinoloneAntimicrob Agents Chemother199943112793279710543767
   PubMed Web of Science ®Google Scholar
• StassHDalhoffAKubitzaDSchuhlyUPharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjectsAntimicrob Agents Chemother1998428206020659687407
   PubMed Web of Science ®Google Scholar
• LabrecheMJFreiCRDeclining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharma codynamics, and clinical outcomesAm J Health Syst Pharm201269211863187023111670
   PubMed Web of Science ®Google Scholar
• EichenbaumGPugsleyMKGallacherDJRole of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2Br J Pharmacol201216651694170722289150
   PubMed Web of Science ®Google Scholar
• CoreyGRStryjewskiMENew rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the goodClin Infect Dis201152Suppl 7S469S47621546623
   PubMed Web of Science ®Google Scholar
• MoranGJKrishnadasanAGorwitzRJEMERGEncy ID Net Study GroupMethicillin-resistant S. aureus infections among patients in the emergency departmentN Engl J Med2006355766667416914702
   PubMed Web of Science ®Google Scholar
• EdelsbergJTanejaCZervosMTrends in US hospital admissions for skin and soft tissue infectionsEmerg Infect Dis20091591516151819788830
   PubMed Web of Science ®Google Scholar
• PallinDJEspinolaJALeungDYHooperDCCamargoCAJrEpidemiology of dermatitis and skin infections in United States physicians’ offices, 1993–2005Clin Infect Dis200949690190719663690
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Staphylococcus aureus resistant to vancomycin – United States, 2002MMWR Morb Mortal Wkly Rep2002512656556712139181
   PubMedGoogle Scholar
• SkiestDJTreatment failure resulting from resistance of Staphylococcus aureus to daptomycinJ Clin Microbiol200644265565616455939
   PubMed Web of Science ®Google Scholar
• Sanchez GarciaMDe la TorreMAMoralesGClinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unitJAMA2010303222260226420530779
   PubMed Web of Science ®Google Scholar
• JainSSelfWHWunderinkRGCDC EPIC Study TeamCommunity-acquired pneumonia requiring hospitalization among U.S. adultsN Engl J Med2015373541542726172429
   PubMed Web of Science ®Google Scholar
• BiedenbachDJTurnerLLJonesRNFarrellDJActivity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strainsDiagn Microbiol Infect Dis201274220420622819604
   PubMed Web of Science ®Google Scholar
• LeBelMValleeFBergeronMGTissue penetration of ciprofloxacin after single and multiple dosesAntimicrob Agents Chemother19862935015052940974
   PubMed Web of Science ®Google Scholar
• GonzalezMAMoranchelAHDuranSMultiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteersAntimicrob Agents Chemother19852822352392939794
   PubMed Web of Science ®Google Scholar
• SorgelFNaberKGKinzigMMahrGMuthPComparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a reviewAm J Med1991916A51S66S1662896
   PubMed Web of Science ®Google Scholar
• HollandMChienSCCorradoMFlorSCRoggeMCThe pharmacokinetic profile of levofloxacin following once- or twice-daily 500mg administrationPoster presented at: Fifth International Symposium on New QuinolonesAugust 25–27, 1994Singapore
   Google Scholar
• StassHKubitzaDPharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in manJ Antimicrob Chemother199943Suppl B839010382880
   PubMed Web of Science ®Google Scholar